Inj. tagraxofusp-erzs 10 mcg
Products billed under this code include Elzonris.
Payment limit per 10 MCG, by effective quarter, 1Q21 to 4Q26. Gaps mean the code was not in that quarter’s file, or CMS gave no payment limit.Products billed under this code include Elzonris.
Payment limit per 10 MCG, by effective quarter, 1Q21 to 4Q26. Gaps mean the code was not in that quarter’s file, or CMS gave no payment limit.From the 4Q26 NDC–HCPCS crosswalk. “Limit / pkg” is the 4Q26 payment limit times the billing units in one package.
| Product | Labeler | NDC | Units / pkg | Limit / pkg |
|---|---|---|---|---|
| Elzonris | Stemline Therapeutics, Inc. | 72187-0401-01 | 100 | $35,729.20 |
| Quarter | Payment limit | Change | Billing unit | Description | Source file |
|---|---|---|---|---|---|
| 4Q26 | $357.292 | −$0.23 | 10 MCG | Inj. tagraxofusp-erzs 10 mcg | v1, posted September 17, 2026 |
| 3Q26 | $357.522 | +$0.243 | 10 MCG | Inj. tagraxofusp-erzs 10 mcg | v1, posted September 15, 2026 |
| 2Q26 | $357.279 | +$0.255 | 10 MCG | Inj. tagraxofusp-erzs 10 mcg | v1, posted September 15, 2026 |
| 1Q26 | $357.024 | +$0.094 | 10 MCG | Inj. tagraxofusp-erzs 10 mcg | v1, posted September 15, 2026 |
| 4Q25 | $356.93 | +$8.314 | 10 MCG | Inj. tagraxofusp-erzs 10 mcg | v1, posted September 8, 2026 |
| 3Q25 | $348.616 | +$10.084 | 10 MCG | Inj. tagraxofusp-erzs 10 mcg | v1, posted March 10, 2026 |
| 2Q25 | $338.532 | −$0.358 | 10 MCG | Inj. tagraxofusp-erzs 10 mcg | v1, posted March 10, 2026 |
| 1Q25 | $338.89 | −$0.144 | 10 MCG | Inj. tagraxofusp-erzs 10 mcg | v1, posted December 19, 2025 |
| 4Q24 | $339.034 | +$12.505 | 10 MCG | Inj. tagraxofusp-erzs 10 mcg | v1, posted June 11, 2025 |
| 3Q24 | $326.529 | −$0.123 | 10 MCG | Inj. tagraxofusp-erzs 10 mcg | v1, posted June 11, 2025 |
| 2Q24 | $326.652 | +$1.097 | 10 MCG | Inj. tagraxofusp-erzs 10 mcg | v1, posted March 11, 2025 |
| 1Q24 | $325.555 | +$1.073 | 10 MCG | Inj. tagraxofusp-erzs 10 mcg | v1, posted December 19, 2024 |
| 4Q23 | $324.482 | +$1.886 | 10 MCG | Inj. tagraxofusp-erzs 10 mcg | v1, posted October 10, 2024 |
| 3Q23 | $322.596 | +$0.416 | 10 MCG | Inj. tagraxofusp-erzs 10 mcg | v1, posted June 5, 2024 |
| 2Q23 | $322.18 | +$2.193 | 10 MCG | Inj. tagraxofusp-erzs 10 mcg | v1, posted February 23, 2024 |
| 1Q23 | $319.987 | +$11.181 | 10 MCG | Inj. tagraxofusp-erzs 10 mcg | v1, posted December 6, 2023 |
| 4Q22 | $308.806 | −$0.60 | 10 MCG | Inj. tagraxofusp-erzs 10 mcg | v1, posted June 22, 2023 |
| 3Q22 | $309.406 | +$13.505 | 10 MCG | Inj. tagraxofusp-erzs 10 mcg | v1, posted June 9, 2023 |
| 2Q22 | $295.901 | −$0.44 | 10 MCG | Inj. tagraxofusp-erzs 10 mcg | v1, posted December 14, 2022 |
| 1Q22 | $296.341 | +$5.974 | 10 MCG | Inj. tagraxofusp-erzs 10 mcg | v1, posted June 8, 2022 |
| 4Q21 | $290.367 | +$6.357 | 10 MCG | Inj. tagraxofusp-erzs 10 mcg | v1, posted June 2, 2022 |
| 3Q21 | $284.01 | −$0.202 | 10 MCG | Inj. tagraxofusp-erzs 10 mcg | v1, posted June 2, 2022 |
| 2Q21 | $284.212 | +$0.885 | 10 MCG | Inj. tagraxofusp-erzs 10 mcg | v1, posted March 1, 2022 |
| 1Q21 | $283.327 | – | 10 MCG | Inj. tagraxofusp-erzs 10 mcg | v1, posted December 10, 2021 |
“Change” is the difference from the previous quarter, shown only when both quarters have a payment limit and the billing unit is the same. “vs. last quarter” and “vs. a year ago” follow the same rule.